{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:31:39Z","timestamp":1781659899514,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,6,17]],"date-time":"2014-06-17T00:00:00Z","timestamp":1402963200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s40265-014-0243-3","type":"journal-article","created":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T07:59:57Z","timestamp":1403164797000},"page":"1111-1125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Pazopanib: A Review of Its Use in the Management of Advanced Renal Cell Carcinoma"],"prefix":"10.1007","volume":"74","author":[{"given":"Paul L.","family":"McCormack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,17]]},"reference":[{"key":"243_CR1","unstructured":"International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. 2014. http:\/\/globocan.iarc.fr\/ . Accessed 20 May 2014."},{"issue":"12","key":"243_CR2","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJM199609193351207","volume":"335","author":"RJ Motzer","year":"1996","unstructured":"Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335(12):865\u201375.","journal-title":"N Engl J Med."},{"issue":"4","key":"243_CR3","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.eururo.2011.06.049","volume":"60","author":"B Ljungberg","year":"2011","unstructured":"Ljungberg B, Campbell SC, Cho HY, et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60(4):615\u201321.","journal-title":"Eur Urol."},{"key":"243_CR4","unstructured":"Ljungberg B, Bensalah K, Bex A, et al. EAU guidelines on renal cell carcinoma. 2013. http:\/\/www.uroweb.org\/gls\/pdf\/10_Renal_Cell_Carcinoma_LRV2.pdf . Accessed 20 May 2014."},{"issue":"9","key":"243_CR5","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.2165\/11591410-000000000-00000","volume":"71","author":"B Escudier","year":"2011","unstructured":"Escudier B, Albiges L. Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma. Drugs. 2011;71(9):1179\u201391.","journal-title":"Drugs."},{"issue":"2","key":"243_CR6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5301\/JN.2010.90","volume":"24","author":"M Zacchia","year":"2011","unstructured":"Zacchia M, Vilasi A, Capasso A, et al. Genomic and proteomic approaches to renal cell carcinoma. J Nephrol. 2011;24(2):155\u201364.","journal-title":"J Nephrol."},{"issue":"6","key":"243_CR7","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1517\/14712598.8.6.779","volume":"8","author":"EC Pfaffenroth","year":"2008","unstructured":"Pfaffenroth EC, Linehan WM. Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther. 2008;8(6):779\u201390.","journal-title":"Expert Opin Biol Ther."},{"issue":"2","key":"243_CR8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000315543","volume":"78","author":"Y Allory","year":"2011","unstructured":"Allory Y, Culine S, de la Taille A. Kidney cancer pathology in the new context of targeted therapy. Pathobiology. 2011;78(2):90\u20138.","journal-title":"Pathobiology."},{"key":"243_CR9","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer (version 3.2014). 2014. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf . Accessed 22 May 2014."},{"issue":"Suppl 7","key":"243_CR10","doi-asserted-by":"crossref","first-page":"vii65","DOI":"10.1093\/annonc\/mds227","volume":"23","author":"B Escudier","year":"2012","unstructured":"Escudier B, Eisen T, Porta C, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii65\u201371.","journal-title":"Ann Oncol."},{"key":"243_CR11","unstructured":"European Medicines Agency. Votrient (pazopanib) 200\u00a0mg film-coated tablet: summary of product characteristics. 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001141\/WC500094272.pdf . Accessed 20 May 2014."},{"key":"243_CR12","unstructured":"GlaxoSmithKline. Votrient (pazopanib) tablets: US prescribing information. 2013. http:\/\/us.gsk.com\/products\/assets\/us_votrient.pdf . Accessed 20 May 2014."},{"issue":"4","key":"243_CR13","first-page":"443","volume":"71","author":"SV Keisner","year":"2011","unstructured":"Keisner SV, Shah SR. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011;71(4):443\u201354.","journal-title":"Drugs."},{"issue":"7","key":"243_CR14","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/1535-7163.MCT-07-0193","volume":"6","author":"R Kumar","year":"2007","unstructured":"Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007;6(7):2012\u201321.","journal-title":"Mol Cancer Ther."},{"issue":"10","key":"243_CR15","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/sj.bjc.6605366","volume":"101","author":"R Kumar","year":"2009","unstructured":"Kumar R, Crouthamel MC, Rominger DH, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer. 2009;101(10):1717\u201323.","journal-title":"Br J Cancer."},{"issue":"4","key":"243_CR16","first-page":"5819","volume":"18","author":"D Canter","year":"2011","unstructured":"Canter D, Kutikov A, Golovine K, et al. Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines. Can J Urol. 2011;18(4):5819\u201325.","journal-title":"Can J Urol."},{"issue":"8","key":"243_CR17","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1470-2045(12)70241-3","volume":"13","author":"HT Tran","year":"2012","unstructured":"Tran HT, Liu Y, Zurita AJ, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 2012;13(8):827\u201337.","journal-title":"Lancet Oncol."},{"issue":"18","key":"243_CR18","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1200\/JCO.2010.32.9110","volume":"29","author":"C-F Xu","year":"2011","unstructured":"Xu C-F, Bing NX, Ball HA, et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol. 2011;29(18):2557\u201364.","journal-title":"J Clin Oncol."},{"issue":"6","key":"243_CR19","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2010.09.028","volume":"54","author":"C-F Xu","year":"2011","unstructured":"Xu C-F, Reck BH, Goodman VL, et al. Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J Hepatol. 2011;54(6):1237\u201343.","journal-title":"J Hepatol."},{"issue":"9","key":"243_CR20","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/sj.bjc.6605653","volume":"102","author":"C-F Xu","year":"2010","unstructured":"Xu C-F, Reck BH, Xue Z, et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert\u2019s syndrome UGT1A1 polymorphism. Br J Cancer. 2010;102(9):1371\u20137.","journal-title":"Br J Cancer."},{"issue":"6","key":"243_CR21","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/clpt.2010.199","volume":"88","author":"EI Heath","year":"2010","unstructured":"Heath EI, Chiorean EG, Sweeney CJ, et al. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther. 2010;88(6):818\u201323.","journal-title":"Clin Pharmacol Ther."},{"issue":"12","key":"243_CR22","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","volume":"15","author":"HI Hurwitz","year":"2009","unstructured":"Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009;15(12):4220\u20137.","journal-title":"Clin Cancer Res."},{"key":"243_CR23","unstructured":"FDA Center for Drug Evaluation and Research. Votrient (pazopanib) hydrochloride tablets: clinical pharmacology and biopharmaceutics review(s). 2009. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022465s000_ClinPharmR.pdf . Accessed 20 May 2014."},{"issue":"9","key":"243_CR24","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1093\/annonc\/mds249","volume":"23","author":"C-F Xu","year":"2012","unstructured":"Xu C-F, Xue Z, Bing N, et al. Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer. Ann Oncol. 2012;23(9):2470\u20131.","journal-title":"Ann Oncol."},{"issue":"6","key":"243_CR25","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061\u20138.","journal-title":"J Clin Oncol."},{"issue":"14","key":"243_CR26","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","volume":"32","author":"B Escudier","year":"2014","unstructured":"Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol. 2014;32(14):1412\u20138.","journal-title":"J Clin Oncol."},{"issue":"8","key":"243_CR27","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722\u201331.","journal-title":"N Engl J Med."},{"issue":"5","key":"243_CR28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/11205480-000000000-00000","volume":"24","author":"M Sanford","year":"2010","unstructured":"Sanford M, Keating GM. Pazopanib: in advanced renal cell carcinoma. BioDrugs. 2010;24(5):279\u201386.","journal-title":"BioDrugs."},{"issue":"3","key":"243_CR29","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2008.21.6994","volume":"28","author":"TE Hutson","year":"2010","unstructured":"Hutson TE, Davis ID, Machiels J-PH, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2010;28(3):475\u201380.","journal-title":"J Clin Oncol."},{"issue":"6","key":"243_CR30","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","volume":"49","author":"CN Sternberg","year":"2013","unstructured":"Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 2013;49(6):1287\u201396.","journal-title":"Eur J Cancer."},{"key":"243_CR31","doi-asserted-by":"crossref","unstructured":"Hawkins RE, Hong SJ, Ulys A, et al. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma (RCC) [abstract no. 5110]. J Clin Oncol. 2009;27(15 Suppl).","DOI":"10.1200\/jco.2009.27.15_suppl.5110"},{"issue":"18","key":"243_CR32","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJMc1400731","volume":"370","author":"RJ Motzer","year":"2014","unstructured":"Motzer RJ, Hutson TE, McCann L, et al. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med. 2014;370(18):1769\u201370.","journal-title":"N Engl J Med."},{"issue":"3","key":"243_CR33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ejca.2011.05.017","volume":"48","author":"D Cella","year":"2012","unstructured":"Cella D, Pickard AS, Duh MS, et al. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. Eur J Cancer. 2012;48(3):311\u201323.","journal-title":"Eur J Cancer."},{"issue":"Suppl 8","key":"243_CR34","first-page":"viii282","volume":"21","author":"V Goodman","year":"2010","unstructured":"Goodman V, Wang K, Pandite L, et al. Incidence and management of hepatic toxicity in pazopanib-treated patients [abstract no. 904P]. Ann Oncol. 2010;21(Suppl 8):viii282.","journal-title":"Ann Oncol."},{"issue":"Suppl 9","key":"243_CR35","doi-asserted-by":"crossref","first-page":"ix290","DOI":"10.1016\/S0923-7534(20)33454-2","volume":"23","author":"FL Lim","year":"2012","unstructured":"Lim FL, Shamash J, Wilson P, et al. Liver toxicity in patients with metastatic renal cell carcinoma treated with pazopanib therapy [abstract no. 880]. Ann Oncol. 2012;23(Suppl 9):ix290.","journal-title":"Ann Oncol."},{"key":"243_CR36","unstructured":"National Cancer Institute Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf . Accessed 20 May 2014."},{"issue":"8","key":"243_CR37","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2165\/11592880-000000000-00000","volume":"28","author":"SK Pal","year":"2011","unstructured":"Pal SK, Vanderwalde A, Hurria A. Systemic therapies for metastatic renal cell carcinoma in older adults. Drugs Aging. 2011;28(8):635\u201349.","journal-title":"Drugs Aging."},{"issue":"6","key":"243_CR38","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11096-005-1319-7","volume":"27","author":"S Sleijfer","year":"2005","unstructured":"Sleijfer S, Bannink M, Van Gool AR, et al. Side effects of interferon-alfa therapy. Pharm World Sci. 2005;27(6):423\u201331.","journal-title":"Pharm World Sci."},{"issue":"22","key":"243_CR39","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584\u201390.","journal-title":"J Clin Oncol."},{"issue":"9605","key":"243_CR40","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103\u201311.","journal-title":"Lancet."},{"issue":"33","key":"243_CR41","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","volume":"26","author":"BI Rini","year":"2008","unstructured":"Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26(33):5422\u20138.","journal-title":"J Clin Oncol."},{"issue":"22","key":"243_CR42","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271\u201381.","journal-title":"N Engl J Med."},{"issue":"2","key":"243_CR43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125\u201334.","journal-title":"N Engl J Med."},{"issue":"9637","key":"243_CR44","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449\u201356.","journal-title":"Lancet."},{"issue":"9807","key":"243_CR45","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","volume":"378","author":"BI Rini","year":"2011","unstructured":"Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931\u20139.","journal-title":"Lancet."},{"issue":"20","key":"243_CR46","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","volume":"27","author":"B Escudier","year":"2009","unstructured":"Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III Treatment Approaches in Renal cancer Global Evaluation Trial. J Clin Oncol. 2009;27(20):3312\u20138.","journal-title":"J Clin Oncol."},{"key":"243_CR47","doi-asserted-by":"crossref","unstructured":"McCann L, Amit O, Pandite L, et al. An indirect comparison analysis of pazopanib versus other agents in metastatic renal cell carcinoma (mRCC) [abstract no. e15128]. J Clin Oncol. 2010;28(15 Suppl).","DOI":"10.1200\/jco.2010.28.15_suppl.e15128"},{"key":"243_CR48","doi-asserted-by":"crossref","unstructured":"Mickisch GH, Schwander B, Escudier BJ, et al. Indirect comparison of bevacizumab plus interferon-alpha-2a versus tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy [abstract no. 4612]. J Clin Oncol. 2010;28(15 Suppl).","DOI":"10.1200\/jco.2010.28.15_suppl.4612"},{"issue":"14","key":"243_CR49","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1200\/JCO.2014.55.1911","volume":"32","author":"MB Garnick","year":"2014","unstructured":"Garnick MB. How to interpret patient preferences in selecting the best drug: are the current measurements up to the job? J Clin Oncol. 2014;32(14):1392\u20133.","journal-title":"J Clin Oncol."},{"key":"243_CR50","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40273-012-0006-5","volume":"31","author":"M Kilonzo","year":"2013","unstructured":"Kilonzo M, Hislop J, Elders A, et al. Pazopanib for the first-line treatment of patients with advanced and\/or metastatic renal cell carcinoma: a NICE single technology appraisal. Pharmacoeconomics. 2013;31:15\u201324.","journal-title":"Pharmacoeconomics."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0243-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-014-0243-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0243-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T20:46:18Z","timestamp":1649450778000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-014-0243-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,17]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["243"],"URL":"https:\/\/doi.org\/10.1007\/s40265-014-0243-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,17]]}}}